98%
921
2 minutes
20
Tumor subclasses differ according to the genotypes and phenotypes of malignant cells as well as the composition of the tumor microenvironment (TME). We dissected these influences in isocitrate dehydrogenase (IDH)-mutant gliomas by combining 14,226 single-cell RNA sequencing (RNA-seq) profiles from 16 patient samples with bulk RNA-seq profiles from 165 patient samples. Differences in bulk profiles between IDH-mutant astrocytoma and oligodendroglioma can be primarily explained by distinct TME and signature genetic events, whereas both tumor types share similar developmental hierarchies and lineages of glial differentiation. As tumor grade increases, we find enhanced proliferation of malignant cells, larger pools of undifferentiated glioma cells, and an increase in macrophage over microglia expression programs in TME. Our work provides a unifying model for IDH-mutant gliomas and a general framework for dissecting the differences among human tumor subclasses.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519096 | PMC |
http://dx.doi.org/10.1126/science.aai8478 | DOI Listing |
Curr Opin Neurol
September 2025
Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ).
Purpose Of Review: Gliomas with mutations in the gene for isocitrate dehydrogenase (IDH) display a unique immune microenvironment that is distinct from IDH-wildtype gliomas. This unique immune microenvironment is shaped by 2-hydroxyglutarate (2-HG), an oncometabolite produced by mutant IDH. These features provide an opportunity to develop and test targeted immunotherapies for IDH-mutant gliomas.
View Article and Find Full Text PDFPharmacoecon Open
September 2025
Acaster Lloyd Consulting Ltd, Lacon House, 84 Theobalds Rd, London, WC1X 8NL, UK.
Background: Isocitrate dehydrogenase-mutant (mIDH) gliomas are malignant central nervous system tumours. After initial resection, patients with mIDH gliomas with favourable prognosis may live without receiving oncologic treatment for years, but ultimately patients will experience recurrence and require radio- and/or chemotherapy (RT/CT). Cost-utility analyses (CUA) can explore the value of treatments that delay recurrence and initiation of RT/CT.
View Article and Find Full Text PDFClin Cancer Res
September 2025
United States Food and Drug Administration, Silver Spring, Maryland, United States.
On August 6, 2024, the U.S. Food and Drug Administration (FDA) granted traditional approval to vorasidenib (VORANIGO, Servier Pharmaceuticals, LLC) for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 or 2 (IDH1 or IDH2) mutation following surgery including biopsy, sub-total resection, or gross total resection.
View Article and Find Full Text PDFClin Neurophysiol
August 2025
Department of Neurosurgery, King's College Hospital NHS Foundation Trust, London, UK.
Objective: Cortical speech mapping using navigated Transcranial Magnetic Stimulation (nTMS) has a variable positive predictive value (PPV) when compared with intraoperative direct electrical stimulation.
Methods: This is a single centre prospective study of all patients undergoing pre-operative nTMS and tractography (frontal aslant tract (FAT) and arcuate fasciculus (AF)) for awake surgery between October 2018 and November 2023. We reviewed operative notes for speech arrest, collected data on demographics, histopathology and pre-/post-operative language assessment.
Ann Diagn Pathol
August 2025
Jinnah Sindh Medical University, Karachi, Pakistan. Electronic address: